In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
The in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii were evaluated. In vitro treatment (100 micrograms of 566C80 per ml for 3 days) of cysts isolated from brains of mice infected for 1, 2, 3, 4, or 9 months resulted in loss of viability of the cysts and did not reveal any influence of the duration of in vivo infection on sensitivity to the drug. In vivo experiments to determine the effect of prolonged treatment with 200 mg of 566C80 per kg of body weight per day on cysts in brains of CBA/Ca mice infected with strain ME49 revealed a steady and significant decline in the numbers of cysts compared with the numbers in untreated controls. Histopathology of brains from control mice revealed inflammatory infiltrates around capillaries and in the parenchymas and meninges which were consistently less evident in the brains of treated mice. In addition, cysts were rarely observed in treated mice, whereas extensive inflammation and large numbers of cysts were found throughout the entire brain in control mice infected for the same period. The reduction in the numbers of cysts was evident as early as day 5 of treatment but was more marked at 8 weeks of treatment. The numbers of cysts in the brains of Swiss Webster mice infected for 3 or 6 months also significantly decreased following treatment for 15 or 30 days with the same dose of 566C80. Our results indicate that 566C80 has excellent activity against cysts of T. gondii both in vivo and in vitro and that sensitivity of the cysts to 566C80 is not affected by the duration of the infection in vivo.
Araujo
F G
FG
Department of Immunology and Infectious Diseases, Palo Alto Medical Foundation, California 94301, USA.
Huskinson-Mark
J
J
Gutteridge
W E
WE
Remington
J S
JS
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D053626:Atovaquone; D001921:Brain / Q000469:parasitology / Q000473:pathology; D005260:Female; D051379:Mice; D008808:Mice, Inbred CBA; D009285:Naphthoquinones / Q000627:therapeutic use*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy* / Q000473:pathology
D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D053626:Atovaquone